From mouse to medicine: Improving preclinical research in Alzheimer ’s disease

Alzheimer’s drug discovery and development is not for the fainthearted. It’s extremely expensive and time-consuming, and the possibility of disappointment looms at every phase of discovery. According to one analysis, half of candidate therapies fail during preclinical research—the phase when important information on feasibility, testing, and drug safety is collected. And, if a promising therapy does advance to a clinical trial, another recent analysis indicates there’s a 98 percent failure rate during phase II and III, primarily due to lack of efficacy.

Source: Inside NIA: A Blog for Researchers - February 1, 2017 Category: Geriatrics Authors: Lorenzo Refolo, Program Director, Division of Neuroscience Source Type: blogs